Physician profile
Frank Arko
NPI 1134181191
$2,612,430.37
in general payments reported to CMS, 2019-2025
42 companies · $224K in 2025
The $224K reported for 2025 was more than what 99% of Vascular Surgery providers received nationally (typical 2025 total: $927).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $241K · 2020: $282K · 2021: $832K · 2022: $307K · 2023: $415K · 2024: $312K · 2025: $224K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $458K · Consulting Fee: $160K · Travel and Lodging: $153K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $125K · Food and Beverage: $42K · Honoraria: $11K · Acquisitions: $1,175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $458,337.00 |
| Consulting Fee | $160,415.00 |
| Travel and Lodging | $153,177.36 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $124,875.00 |
| Food and Beverage | $42,158.94 |
| Honoraria | $10,900.00 |
| Acquisitions | $1,174.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Penumbra, INC. | $682,069.32 | 2019-2025 | Indigo System, Ruby Coil, Penumbra System |
| Boston Scientific Corporation | $645,703.79 | 2019-2025 | General - Therapies, Enroute Transcarotid Neuroprotection System, Avvigo Guidance System |
| Medtronic, INC. | $373,539.41 | 2021-2025 | Endurant Iis, Valiant Captivia, Heli-Fx Endoanchor System |
| Shockwave Medical, INC | $329,965.91 | 2019-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Intravascular Lithotripsy (Ivl) System With The Shockwave M5+ |
| Medtronic Vascular, INC. | $188,332.87 | 2019-2020 | |
| Globus Medical, INC. | $175,894.46 | 2019-2025 | Corbel, Alif, Mars Anterior Retractor |
| W. L. Gore & Associates, INC. | $79,132.86 | 2019-2025 | Gore Tag Thoracic Branch Endoprosthesis, Gore Tag Conformable Thoracic Stent Graft, Gore Excluder Iliac Branch Endoprosthesis |
| Philips North America LLC | $33,959.83 | 2019-2024 | (6554) Peripheral Vascular Undivided, (Br5) Peripheral Ivus |
| Bolton Medical INC | $32,137.84 | 2020-2025 | Treo Abdominal Stent-Graft System, Relay Thoracic Stent-Graft With Plus Delivery System |
| Silk Road Medical, INC. | $25,446.38 | 2019-2024 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter |
| Bard Peripheral Vascular, INC. | $14,360.10 | 2021-2023 | |
| Artivion, INC. | $11,097.27 | 2021-2025 | Jotec Products |
| Contego Medical, INC | $4,842.40 | 2022 | |
| Atrium Medical Corporation | $3,624.52 | 2019 | |
| Endologix LLC | $3,375.79 | 2019-2023 | Torus Stent Graft System, Endocross Device, Afx2 Bifurcated Endograft System |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vesalio, INC. | $2,500.00 | 2024 | |
| Heartflow, INC. | $1,428.73 | 2019-2025 | Ffrct |
| Cook Medical LLC | $1,072.66 | 2019-2023 | Zilver Ptx, Performer |
| Cagent Vascular INC | $1,062.50 | 2024-2025 | Serrantor |
| Shape Memory Medical INC. | $516.06 | 2022-2025 | Impede Embolization Plug |
| Edwards Lifesciences Corporation | $256.32 | 2023 | Hemosphere |
| Cardiovascular Systems INC. | $205.92 | 2019 | |
| Viz.Ai, INC. | $194.46 | 2021-2022 | |
| Surmodics, INC. | $193.27 | 2021-2022 | |
| Cvrx, INC. | $189.28 | 2024 | Barostim Neo System |
| Siemens Medical Solutions USA, INC. | $170.24 | 2025 | Acuson Origin Diagnostic Ultrasound System |
| Getinge USA Sales, LLC | $159.16 | 2020-2022 | |
| Inspiremd Ltd | $155.00 | 2024 | Cguard |
| Angiodynamics, INC. | $142.77 | 2020 | |
| Humacyte Global, INC. | $138.30 | 2025 | |
| Abbott Laboratories | $135.75 | 2024 | Supera |
| Terumo Medical Corporation | $105.16 | 2025 | Navicross, Angio-Seal |
| Veryan Medical Incorporated | $89.96 | 2020 | |
| Elutia, INC. | $48.47 | 2019 | |
| Atricure, INC. | $42.81 | 2023 | |
| Davol INC. | $33.43 | 2019 | |
| Ethicon US, LLC | $32.54 | 2024 | Prolene |
| Venturemed Group, INC. | $26.44 | 2019 | |
| Lemaitre Vascular, INC. | $24.08 | 2025 | Hydro Lemaitre Valvulotome |
| Cardiva Medical, INC. | $18.11 | 2025 | Cardiva Vascade 6/7f Vcs |
| Centerline Biomedical INC. | $6.20 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$9,881.83 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
$8,168.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Arko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.